Hospital Clínico de Valencia

Valencia 46010

1 studies enrolling now · 20 studies all time

What they study most

Bladder Carcinoma, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Chronic Kidney Disease, Colorectal Cancer Metastatic, Colorectal Neoplasms, Cutaneous Melanoma, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Nephropathies

Studies at this site

• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation — Recruiting now
• A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) — Completed
• A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer — Completed
• The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread — Completed
• A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease — Completed
• A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease — Completed
• Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment — Completed
• A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. — Completed
• A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms. — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms — Completed
• Sym004 Versus Futuximab or Modotuximab in Patients With mCRC — Stopped early
• CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes — Completed
• Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer — Completed
• Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) — Completed
• Nintedanib (BIBF 1120) in Mesothelioma — Stopped early
• LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy — Completed
• Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) — Completed
• Linagliptin as Add on to Basal Insulin in the Elderly — Completed
• Reversal of Dabigatran Anticoagulant Effect With Idarucizumab — Completed